Prime Medicine, Inc.

PRMENASDAQHealthcareBiotechnology

$3.61- (-)1Y −37.76%

As of Oct 15, 2026 close

Market cap: $639.78M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $2.67$6.65
Volume (live): -
Avg. volume (3M): 4.32M

Prime Medicine, Inc. (PRME) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Prime Medicine, Inc. stock.

Analyst Consensus Rating

Investment consensus from 10 professional research analysts

Consensus Rating

Buy

Based on 10 unique analysts

(12 total ratings in last 90 days)

High Confidence∞:1 Buy/Sell

Average Price Target

$7.86

+117.73% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest PRME Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 5, 2026	Cory Jubinville, PhD	LifeSci Capital	Maintains	Buy	$6.00
Oct 1, 2026	Arthur He CFA	HC Wainwright	Reiterates	Buy	$8.00
Sep 25, 2026	Keay Nakae	Chardan Capital	Maintains	Buy	$7.00
Sep 25, 2026	Joseph Thome	TD Cowen	Maintains	Buy	-
Sep 25, 2026	David Lebowitz	BMO Capital	Maintains	Buy	$9.00
Sep 25, 2026	Kostas Biliouris	Oppenheimer	Reiterates	Buy	$11.00
Sep 24, 2026	Keay Nakae	Chardan Capital	Maintains	Buy	$7.00
Sep 24, 2026	Joseph Thome	TD Cowen	Maintains	Buy	-
Aug 18, 2026	Unknown Analyst	BMO Capital	Initiates	Buy	$9.00
Aug 10, 2026	Terence Flynn	Morgan Stanley	Reiterates	Hold	-
Aug 6, 2026	Boris Peaker	JonesTrading	Maintains	Buy	$5.00
Jul 30, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Buy	-

Cory Jubinville, PhD

LifeSci Capital

BuyMaintains

$6.00

Oct 5

Arthur He CFA

HC Wainwright

BuyReiterates

$8.00

Oct 1

Keay Nakae

Chardan Capital

BuyMaintains

$7.00

Sep 25

Joseph Thome

TD Cowen

BuyMaintains

Sep 25

David Lebowitz

BMO Capital

BuyMaintains

$9.00

Sep 25

Kostas Biliouris

Oppenheimer

BuyReiterates

$11.00

Sep 25

Keay Nakae

Chardan Capital

BuyMaintains

$7.00

Sep 24

Joseph Thome

TD Cowen

BuyMaintains

Sep 24

Unknown Analyst

BMO Capital

BuyInitiates

$9.00

Aug 18

Terence Flynn

Morgan Stanley

HoldReiterates

Aug 10

Boris Peaker

JonesTrading

BuyMaintains

$5.00

Aug 6

Zacks Equity Research

BuyInitiates Coverage

Jul 30

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 5, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for PRME?

The analyst consensus rating for PRME is Buy, based on the latest ratings from 10 analysts over the last 90 days.

What is the average price target for PRME?

The average 12-month price target for PRME is $7.86, representing an upside of 117.7% from the Oct 15, 2026 close of $3.61.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.